Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain

Endo Pharmaceuticals

Status and phase

Completed

Phase 3

Conditions

Chronic Pain

Treatments

Drug: Oxymorphone Extended Release

Study type

Interventional

Funder types

Industry

Identifiers

NCT00225797

EN3202-031

Details and patient eligibility

About

The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in non-cancer patients with chronic low back pain.

Full description

Patients with low back pain who are sub-optimally responsive to their current analgesic treatment begin open-label treatment with oxymorphone extended release (ER). During the Open-Label Titration Period, patients will receive daily oxymorphone ER by mouth (PO) q12h. The investigator will initiate the Open-Label Titration Period using study drug at a dose of 5 mg PO q12h for 2 days; thereafter, patients will continue receiving 5 mg q12h or be titrated at increments of 5-10 mg q12h every 3-7 days until stabilization is achieved. The goal of the Open-Label Titration Period is to determine for each patient a fixed dose of study medication that is tolerated and achieves adequate analgesia. Stabilized patients will be randomiozed to either continue with current dose of oxymorphone ER or receive placebo for a total duration of 12 weeks.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males or females 18 years of age or older
opioid naïve
Have an initial pain intensity score of at least 50 mm VAS
In good health as determined by the investigator on the basis of medical history and physical examination
Have moderate to severe chronic non-neuropathic LBP that has been present daily for at least several hours per day for a minimum of three months prior to the Screening
Any adjunct therapy for back pain such as physical therapy, biofeedback therapy, acupuncture therapy or herbal remedies, based on the patient's current status should remain unchanged during the period of participation of the patient
Written informed consent

Exclusion criteria

Pregnant and/or lactating
Radiculopathy, fibromyalgia, reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, severe lower extremity weakness or numbness, bowel or bladder dysfunction secondary to cauda equina compression, diabetic amyotrophy, meningitis, discitis, or back pain due to secondary infection or tumor
Cannot or will not agree to stop local regional pain treatments during the study (nerve/plexus blocks or ablation, neurosurgical procedures for pain control, or inhalation analgesia). The patient must not have a nerve/plexus block within 4 weeks of screening
Intend to alter physical therapy regimen during the study.
Surgical procedures directed towards the source of back pain within 6 months of screening
Pain which is secondary to confirmed or suspected neoplasm
Dysphagia or difficulty swallowing tablets or capsules, or an inability to take oral medication
Significant prior history of substance abuse or alcohol abuse
Use of any investigational medication within 30 days prior to the first dose of study medication
Previous exposure to oxymorphone
History of clinically significant intolerance to oxymorphone or a known hypersensitivity to opioid analgesics
History of seizure
Ileostomy or colostomy
Use of MAO inhibitor within 14 days prior to the start of study medication
Other clinically significant conditions as judged by the investigator